SKV-19071-84537
2 vaccinations
2 coded responses
24 check-ins
2 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 597 / MT
- Registered
- 2021-04-13
- Relationship
- Self
- Race
- Multiracial
- Ethnicity
- Not Hispanic or Latino
Registered dependents
S7K-16792-85993
Child or adolescent in my care · Male · 2022-07-12
MH6-13141-74627
Child or adolescent in my care · Female · 2022-07-12
Timeline
-
2021-04-13
Registered in v-safe
-
2021-04-14
Dose 1 — Pfizer-BioNTech
- 2021-04-14
- 2021-04-15
-
2021-04-16
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
-
2021-04-16
Report sent to call center — days 1–6 daily, dose 1Be unable to do your normal daily activities1 call case(s)
- 2021-04-17
- 2021-04-19
- 2021-04-20
- 2021-04-21
- 2021-04-28
-
2021-05-04
Dose 2 — Pfizer-BioNTech
- 2021-05-04
-
2021-05-05
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Site: Pain · Fever · Chills, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
- 2021-05-06
- 2021-05-07
- 2021-05-08
- 2021-05-09
- 2021-05-10
- 2021-05-11
- 2021-05-18
- 2021-05-25
- 2021-06-01
- 2021-06-08
- 2021-06-15
-
2021-08-03
Survey response — 3 months, dose 2MedDRA: Headache, Nasopharyngitis, Rhinorrhoea — Feeling: Good · Be unable to do your normal daily activitiesFree text: Runny nose, headaches. Regular cold.MedDRA releases: 2021-09,2024-11 · check-in free text available
- 2021-11-02
-
2022-05-06
Survey response — 12 months, dose 2MedDRA: Adenomyosis — Feeling: GoodFree text: AdenomyosisMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-14 | Pfizer-BioNTech | |
| 2 | 2021-05-04 | Pfizer-BioNTech |
Call center
1 call center case
1 priority 2/3 (triaged and no follow up)
Free text
Release 9 — 3 months, dose 2
Symptoms: Runny nose, headaches. Regular cold.
Release 11 — 12 months, dose 2
Symptoms: Adenomyosis
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Adenomyosis | · | · | ✓ |
| SD | Headache | ✓ | · | ✓ |
| SD | Nasopharyngitis | ✓ | · | ✓ |
| SD | Rhinorrhoea | ✓ | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release